Laura Gil Alberdi

Laura Gil Alberdi is an outstanding scientist and entrepreneur, with a professional career focused on the field of molecular biology and human genetics. She has a PhD in molecular biology and 25 years of teaching in human genetics at the Alfonso X el Sabio University. Currently, she holds the position of CEO of Cromatrix leading the line of aging and Alzheimer’s treatment. She has recently identified new biomarkers for the diagnosis of this pathology in vivo. One of her most notable scientific achievements is her contribution to the development of a new hypothesis on the onset and development of sporadic Alzheimer’s associated with neuronal aging, focused on epigenetic and nuclear changes. This theory, called nuclear pathology, represents an innovative approach that complements the existing understanding of the disease, which has traditionally focused on cytoplasmic pathology.